Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: A multicentre, first-in-human, open-label, phase 1-2 study Academic Article uri icon

Overview

MeSH Major

  • Curriculum
  • Games, Experimental
  • Internship and Residency
  • Pediatrics
  • Teaching

abstract

  • Astellas Pharma, National Cancer Institute (Leukemia Specialized Program of Research Excellence grant), Associazione Italiana Ricerca sul Cancro.

publication date

  • January 2017

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S1470-2045(17)30416-3

Additional Document Info